Dr. Moore, a former United States Assistant Surgeon General, provides strategic planning for AREV’s nutritional and drug discovery platforms, as Chairman of the Scientific Advisory Board. Dr. Moore is a member of the board of advisers of the Institute of Human Virology (IHV) and the board of directors of the Global Virus Network associated with IHV, University of Maryland Medical Center. IHV is the first research institute in the U.S. to link basic science, population studies, and clinical trials in an effort to develop new vaccines and treatments; its 80 faculty members contribute to research on pandemic pathogens, ranging from COVID-19 to HIV.
Dr. Moore served with the United States Department of Health and Human Services (HHS) and was responsible for the last 12 years of his career for global development support within the Office of the Secretary, HHS, with primary emphasis on implementing innovations in essential health care commodity procurement programs for resource-challenged countries. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service entering with the U.S. National Institutes of Health (NIH) and rising to the rank to Rear Admiral. Dr. Moore worked at the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming senior epidemiologist within the National Institute for Occupational Safety and Health of the U.S. Centers for Disease Control and Prevention (CDC), where he also served as an epidemic intelligence service officer.
Dr. Moore has conducted clinical research on infectious diseases, has evaluated the safety and effectiveness of medical devices, and has conducted relevant epidemiological research on the utilization experience and human health effects of medical devices and radiation. Dr. Moore served on the Fogarty International Center advisory board of directors, NIH, from 2009 to 2013. He served on the alumni board of directors for the school of public health, University of Michigan, from 1987 to 1993. Dr. Moore served on the dean's alumni council, Bloomberg School of Public Health, at Johns Hopkins University, from 1998 to 2002. He has also served as an affiliate associate professor of environmental health for the University of Washington, Seattle, from 1994 to 2003, and as an adjunct professor of epidemiology for the Medical University of Southern Africa, Pretoria, South Africa, from 1999 to 2002. He served on the board of directors for the Africa Center for Health and Human Security, at George Washington University, from 2006 to 2009.
Dr. David Miller is an AIDS treatment activist and skilled advocate within the biotechnology sector, working to advance the cascade of discovery and development of innovative therapeutics. He is the former chair and current member of the Community Advisory Board of the University of Rochester Adult AIDS Clinical Trials Group (ACTG) of the NIH. He attends global health and infectious disease conferences each year, reporting key developments in the print and image media and has co-authored several peer-reviewed conference abstracts. Dr. Miller also served as co-chair of the New York City HIV Planning Council Advisory Group, which oversees the distribution of Ryan White CARE Act grants, on the Bronx HIV CARE Network, as the HIV/AIDS Treatment Education Coordinator at Health People Inc., and on the Cornell ACTG Community Advisory Board. He is a former board member of the AIDS Institute, a leading advocacy organization for federal support of people with HIV/AIDS and their healthcare providers. Dr. Miller was a longtime member of ACT UP NY and has participated in numerous demonstrations for access to essential life-saving medicines and nutritional supplements for people living with HIV/AIDS.
Dr. Dhanabalan advises AREV on product development and formulation. She is the founder and CEO of Global Health & Hygiene Solutions LLC, whose mission is to promote wellness and prevent illness locally and globally and runs an independent practice at Uplifting Health & Wellness in Cambridge, Massachusetts. Dr. Dhanabalan, a fellow of the American Academy of Family Physicians, graduated from UMDNJ, Newark, New Jersey with her medical degree and trained in family medicine at MUSC in Charleston, South Carolina; she earned her master's degree in public health from Harvard’s School of Public Health in Boston, Massachusetts and continued her training at Harvard in occupational and environmental medicine.
Dr. Robert Melamede received his doctorate degree in molecular genetics and biochemistry from the University of the City of New York Graduate Center, focusing on base excision repair of free radical damages in DNA. For decades, he led laboratory efforts in a world-class, federally funded lab where he discovered endonuclease VIII. Dr. Melamede did a sabbatical at the Scripps Institute and subsequently established an in vitro monoclonal antibody facility at the University of Vermont, developing antibodies to free radical damages in DNA and to DNA repair enzymes. Working with a collaborator, Dr. Melamede worked on metabolism and cancer cells as a professor and chair of the biology department at the University of Colorado at Colorado Springs. He co-founded Cannabis Science, Inc., a public company, retiring as the company’s chief executive in 2014. Dr. Melamede continues his innovative research in the private sector.
Dr. Harold Smith is the founder, CEO, and president of OyaGen, Inc., a biotechnology company developing therapeutics for various disease states including HIV and cancer. Dr. Smith is also a tenured professor of biochemistry and biophysics at the University of Rochester, School of Dentistry and Medicine, with additional appointments as a professor in genetics and pathology and as a member of the Center for RNA Biology.
Under Dr. Smith leadership, OyaGen has discovered and patented first-in-class lead (Irino-L) that enables innate immunity against HIV as a treatment with curative potential for HIV/AIDS and recently sold patented best-in-class Oya1 as candidate treatment for infections due to Coronavirus, Ebola virus, Lassa virus and Pox virus. In addition, Oyagen’s laboratory, platform technology, and broad technical knowhow has enabled the development of a cancer drug discovery platform based on gene editing enzymes. Oyagen is located in Rochester, New York in a state-of-the-art laboratory within the Rochester BioVenture Center.
Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences, College of Pharmacy at Oregon State University. Research Interests include: Cancer prevention by dietary antioxidants, and prostate cancer prevention by the carotenoid lycopene. Mass spectrometry-based pharmacological screening of natural products and combinatorial libraries for drug discovery, and high throughput screening to asses drug metabolism, toxicity and bioavailibility.